Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04590066 · ClinicalTrials.gov registry record · NA
Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 734,383
- Enrollment target
NCT04590066: Completed NA study, sponsored by University of Pennsylvania.
NCT04590066 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 734,383 participants, above the 1,391-participant average among 58,714 other NA trials with a reported enrollment target (52695% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04590066, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 734,383 participants
- Enrollment target
Study Summary
This research aims to identify which behavioral science strategies are most effective at increasing flu vaccination rates overall and based on patients' individual characteristics. Past behavioral science interventions have shown promise in increasing flu vaccinations. For example, successful interventions have encouraged people to make concrete plans for when they will get a flu vaccination, sent automated calls or text messages reminding patients to get a flu vaccination , or provided financial incentives for getting vaccinated. Although these results are promising, these studies have been conducted in isolation on different populations, which makes it difficult to compare their interventions' effectiveness or to have enough power to reliably detect differing responses to interventions based on individual characteristics. This research will simultaneously test 22 different SMS interventions to increase flu vaccinations compared to a holdout control condition in a "mega-study" and apply machine learning to identify which interventions work best for whom. The interventions are designed by behavioral science experts from the Behavior Change for Good Initiative (BCFG), Penn Medicine Nudge Unit (PMNU), and Geisinger Behavioral Insights Team (BIT). Customers of a large retail pharmacy who received a flu shot from the pharmacy last year and receive SMS notifications will be included in this study. We expect this to include approximately 1.2 million participants. The specific aims of this research are to identify (1) which behavioral science strategies effectively increase flu vaccination rates overall, and (2) which strategies are most effective for different subgroups (e.g., based on age, gender, race).
Primary Outcome
The primary outcome measure is whether participants receive a flu shot at our retail pharmacy partner by December 31, 2020 (as recorded in their pharmacy records) after receiving the SMS intervention on September 25, 2020. Participants who receive a flu shot before September 25, 2020 when they received the SMS intervention will be excluded from the analyses.
Interventions
- BEHAVIORAL Flu shot text messages
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 734,383 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2020-12-31 |
| Phase | NA |
What the finished NCT04590066 record still lists
NCT04590066 is an interventional study that assigns participants to a tested intervention. Its 734,383 participants enrollment target places it among the larger protocols in the corpus, above the 1,391-participant average among 58,714 other NA trials with a reported enrollment target (52695% higher).
The record links to 0 conditions, and to 1 intervention - of which Flu shot text messages is the first listed.
NCT04590066 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04590066 about?
NCT04590066 is a clinical study titled "Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy". This research aims to identify which behavioral science strategies are most effective at increasing flu vaccination rates overall and based on patients' individual characteristics. Past behavioral science interventions have shown promise in increasing flu vaccinations. For example, successful interv...
What is the current status of trial NCT04590066?
This trial is currently completed. It is a NA study. The enrollment target is 734,383 participants. The study started on 2020-09-25. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT04590066?
The interventions under investigation include: Flu shot text messages (BEHAVIORAL).
Who is sponsoring clinical trial NCT04590066?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04590066's enrollment target sits among peer trials
734,383 1st of 2000 higher than 2,000 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01073475 · 950,000 participants
Maternal Newborn Health Registry
- NCT06029933 · 960,000 participants
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
- NCT05065060 · 500,000 participants
Parkinson Progression Marker Initiative Online (PPMI Online)
- NCT06017687 · 500,000 participants · NA
Data Collection and Evaluation of OptiBP Under Investigational Use
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI